5409372026-04-012026-06-305409372026-04-012026-06-30in-capmkt:OtherExpenses1Member5409372026-04-012026-06-30in-capmkt:OtherExpenses2Member5409372026-04-012026-06-30in-capmkt:OtherExpenses3Member5409372026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRxbrli:pureiso4217:INRxbrli:shares540937MEDICONOTLISTEDINE630Y01024MEDICO REMEDIES LIMITEDMain BoardEquity2026-04-012027-03-312026-08-132026-08-10INRLakhsQuarterlyFirst quarterSingle segmentmanufacturer and exporter of pharmaceutical formulations2026-08-1315:30:002026-08-1317:20:00Not applicablefalsefalseThe Company has not made any default on loans and debt securities and hence, the said disclosure is not applicable to the Company.2026-04-012026-06-30UnauditedStandalone69400600011686000705692000471953000120420007358600019576000406200072340008384400067229700033395000033395000710000011160008216000025179000000025179000-2770002490200016596800020.30.3000.30.30.00010.0010.11Notes: <br /> 1. The above unaudited standalone financial results of the company were reviewed and recommended by the audit committee on August 13, 2026 and subsequently approved by the Board of Directors at its meeting held on August 13, 2026. The review report has been filed with stock exchange and is available on the Company’s website. <br /> <br /> 2. The figures for the quarter ended on 31 st March 2026 are balancing figures between the audited figures for the year ended 31 st March 2026 and reviewed year to date figures upto the third quarter of that financial year. <br /> <br /> 3.The standalone financial results for the quarter ended on 30th June, 2026 have been subjected to Limited Review by statutory auditors of the company and the statutory auditors have issued unmodified report on unaudited financial results. <br /> <br /> 4.The above financial results have been prepared as per IND AS and all standards and requirements of IND AS are complied with by the company. <br /> <br /> 5.Medico Remedies Limited is a pharmaceutical formulation manufacturing company and the management reviews the performance of the company as a single operating segment in accordance with IND-AS 108 “Operating Segments” notified pursuant to Companies (Accounting Standard) Rules, 2015. Accordingly, no segment information/segment reporting has been furnished within. Details of geographical segments are disclosed below: <br /> <br /> PARTICULARS QE 30.06.2026 QE 31.03.2026 <br /> Amount (Rs. In Lakh) Amount (Rs. In Lakh) <br /> 1)Sales of products within India 2633.62 274.48 <br /> 2)Sales of products Outside India 4269.74 5364.29 <br /> Sub- Total 6903.36 5638.77 <br /> <br /> 6.Previous periods figures have been regrouped / reclassified where required to make them compatible with the figures of current periods. <br /> <br /> 7.The company does not have any subsidiary/associate/joint venture company as on 30th June 2026. <br /> <br /> 8.The result for the quarter ended June 30, 2026 is available on the BSE Limited website (URL: www.bseindia.com), NSE Limited website (URL: www.nseindia.com) and on the Company’s website (URL: www.medicoremedies.com) <br /> Manufacturing Expense34924000Selling and Distribution Expenses33466000Other Business Administrative Expense15454000Re-measurement gain (Losses) on defined benefit plans-370000-370000-930000-277000